Glaukos Corporation (GKOS)
Glaukos Corporation (GKOS) is a medical device company that specializes in innovative treatments for glaucoma, corneal disorders, and other ocular diseases. It is known for its development of minimally invasive devices, including the iStent trabecular micro-bypass stent, which helps lower intraocular pressure and reduces reliance on medication for glaucoma patients. The company focuses on advancing ophthalmic healthcare through novel, minimally invasive surgical solutions.
Company News
Nicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.
Glaukos Corporation is focused on developing and commercializing surgical devices and pharmaceutical therapies for glaucoma treatment. The company's iStent product line and global glaucoma and Corneal Health franchises are performing well, despite competition and supply chain challenges. Glaukos is also advancing its pipeline, including iDose TRE...
Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.
Truist Securities has raised its price target for Glaukos Corporation shares to $141, citing the company's strong market position and the potential of its iDose product. The firm maintains a Buy rating on the stock.
Wall Street coasted into the close on Friday but still had a good week.